LCM
CORT icon

Laurion Capital Management’s Corcept Therapeutics CORT Stock Holding History

Laurion Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,827
Closed -$354K – 283
2025
Q2 		$354K Buy
+4,827
New +$350K 0.01% 284
2020
Q4 		– Sell
-37,897
Closed -$660K – 686
2020
Q3 		$660K Buy
+37,897
New +$604K 0.01% 524
2018
Q2 		– Sell
-28,594
Closed -$470K – 1358
2018
Q1 		$470K Buy
28,594
+15,394
+117% +$285K ﹤0.01% 1025
2017
Q4 		$238K Sell
13,200
-31,761
-71% -$575K ﹤0.01% 1393
2017
Q3 		$868K Buy
+44,961
New +$670K ﹤0.01% 1021

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Laurion Capital Management's CORT Position: Q3 2025 in Review

Laurion Capital Management sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 4,827 shares — an estimated $354K sold.

Laurion Capital Management first reported a position in CORT in Q3 2017 and held it in 5 quarters. The position peaked at $868K in Q3 2017. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Laurion Capital Management reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Laurion Capital Management sold 4,827 Corcept Therapeutics shares in Q3 2025, an estimated $354K.
  • Laurion Capital Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 5 quarters.
  • Laurion Capital Management's Corcept Therapeutics position peaked at $868K in Q3 2017.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Laurion Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.